Healthcare / Medical DevicesStockholm
$13.10
-1.30 (-9.03%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-13.1M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$247M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.8%
↓Gross Margin
99.5%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+39.9%
FCF CAGR
—
FCF margin
-29.3%
FCF / Net income
1.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.4M · net income $-8.8M · FCF $-13.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.4M | $44.4M | $44.0M | $37.1M | $16.2M |
| Net Income | $-8.8M | $-8.8M | $-12.6M | $-9.2M | $-15.9M |
| EBITDA | $-2.0M | $-2.0M | $-3.7M | $-3.6M | $-11.9M |
| EPS | -0.46 | -0.46 | -0.67 | -0.50 | -1.01 |
| Gross Margin | 99.5% | 99.5% | 109.1% | 103.9% | 102.5% |
| Operating Margin | -20.9% | -20.9% | -20.0% | -27.1% | -101.0% |
| Net Margin | -19.7% | -19.7% | -28.5% | -24.9% | -98.0% |
| Balance Sheet | |||||
| Current Ratio | 2.53 | 2.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.0M | $-13.0M | $-20.4M | $-13.1M | $-22.8M |
| Returns | |||||
| ROE | -14.8% | -14.8% | -18.0% | -12.0% | -19.5% |
| Valuation | |||||
| P/B | 4.19 | 4.19 | 6.03 | 8.37 | 2.31 |
| Growth & Yield | |||||
| Revenue Growth | 1.0% | 1.0% | 18.6% | 128.6% | — |
| EPS Growth | 31.3% | 31.3% | -34.0% | 50.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.67 → -0.46
Residual
-24.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.